Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023
STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,…
STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,…
WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Innovation Pharmaceuticals (OTCQB:IPIX) (“the…
WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Innovation Pharmaceuticals (OTCQB:IPIX) (“the…
ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions…
ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions…
The LIGHTHOUSE study evaluating the safety and tolerability of investigational gene therapy ATSN-201 is enrolling…
The LIGHTHOUSE study evaluating the safety and tolerability of investigational gene therapy ATSN-201 is enrolling…
Financing led by RA Capital Management with participation from Insight Partners, NVIDIA, and Gaingels Superluminal…
Financing led by RA Capital Management with participation from Insight Partners, NVIDIA, and Gaingels Superluminal…
$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into…
$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into…
Phase 2b trial of TOUR006 is expected to report top-line clinical data in the first…
Phase 2b trial of TOUR006 is expected to report top-line clinical data in the first…
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions…
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions…
WATERTOWN, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage…
WATERTOWN, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage…
WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late…
WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late…
Sub-group analyses of patients with early Parkinson’s disease (PD) at different age groups or baseline…